The pleiotropic effect of statins in haemodialysis patients is not the consequence of an inhibition of LDL oxidation by myeloperoxidase [8]

Nephrology Dialysis Transplantation

Volumn 21, Issue 9, 2006, Pages 2672-2674

  Van Antwerpen, P ^a   Zouaoui Boudjeltia, K ^a   Vaes, M ^a   Babar, S ^a   Madhoun, P ^b   Moguilevsky, N ^c   Vanhaeverbeek, M ^a   Neve J ^a   Ducobu, J ^d  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b CHU Andre Vesale   (Belgium)

^c UNIVERSITY OF NAMUR   (Belgium)

^d Centre Hospitalier Universitaire de Tivoli   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; MYELOPEROXIDASE; SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXIDASE;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LETTER; LIPID OXIDATION; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; TREATMENT DURATION; ANIMAL; COMPARATIVE STUDY; METABOLISM; OXIDATION REDUCTION REACTION; RAT; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ANIMALS; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATION-REDUCTION; PEROXIDASE; RATS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33750141255     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl143     Document Type: Letter

References (12)

1. Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: The underestimated modifying effects of heparin. Am J kidney dis 2006; 47: 37-41
2. Wu CC, Chen, JS, Wu WM et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible membranes. Nephrol Dial Transplat 2005; 20: 1134-1139
3. Zhang R, Brennan ML, Fu X et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-2142
4. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Comm 2005; 331: 442-451
5. Shishehbor MH, Brennan ML, Ronnier J et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108: 426-431
6. Tiefenbacher CP, Kapitza J, Dietz V et al. Reduction of myocardial infarct size by fluvastatin. Am J Pysiol Heart Circ Physiol 2003; 285: H59-H64
7. Stenvinkel P, Rodriguez-Ayala E, Massy ZA et al. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2006; in press
8. Carr AC, Myzak MC, Stocker R et al. Myeloperoxidase binds to low-density lipoprotein: Potential implications for atherosclerosis. FEBS Letters 2000; 487: 176-180
9. Hazell JL, Van den Berg JJM, Stocker R. Oxidation of low density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem J 1994; 304: 297-304
10. Moguilevsky N, Zouaoui Boudjeltia K, Babar S et al. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem Biophys Res Comm 2004; 323: 1223-1228
11. 2/Chloride system to inhibit LDL oxidation. Biochem Biophys Res Comm 2005; 337: 82-88
12. Nève J, Parij N, Moguilevsky N. Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs investigated with a human recombinant enzyme. Eur J of Pharm 2001; 417: 37-43